Details

Autor(en) / Beteiligte

• Parisi, Vincenzo
• Ziccardi, Lucia
• Roberti, Gloria
• Tanga, Lucia
• Manni, Gianluca

Titel

Commentary: Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma

Ist Teil von

• Frontiers in aging neuroscience, 2016-08, Vol.8, p.194-194

Ort / Verlag

Switzerland: Frontiers Research Foundation

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Interestingly, the machine detected the molecule very well as the signal was present always at the same time and in all four transitions used. [...]we concluded that the molecule reached the vitreous. At this moment, all patients completed 30 months of follow-up and any patient treated with OMK1®, showed none of the ocular adverse side effects mentioned before. [...]our works (Roberti et al., 2014; Parisi et al., 2015) provide a sound evidence that (1) the Citicoline reaches the vitreous in animal model; (2) there is a proof that Citicoline may reach the vitreous and the retinal structures in patients with glaucoma: this is derived by the effects of Citicoline eye drops on the retinal increased function (neuroenhancement) with consequent improvement of the neural conduction along the visual pathways and related reduction of the mean defects values (improvement of the visual field); (3) by using BAK as vehicle for Citicoline eye drops at the concentration of 0.01% any type of ocular surface changes were not detected during our previous or actual (30 months) follow-up and thus the eye drops are well tolerated. [...]all this lead us to believe that Citicoline eye drops can be endorsed in the management of glaucoma with the possible aim to reduce the progression of visual glaucomatous dysfunction.